Walder Wyss advises BioVersys on its Series B Financing Round
Walder Wyss advises BioVersys, a biotech company focusing on research and development of small molecules which switch off drug resistance against antibiotics, on its Series B Financing Round. The financing round amounts to CHF 19 mio. and was subscribed by existing shareholders as well as new investors.